Market Overview

Illumina Q2 Earnings Preview

Share:
Related ILMN
The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage
The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic

On Monday, Illumina (NASDAQ: ILMN) will release its latest earnings report. Benzinga's outlook for Illumina is included in the following report.

Earnings and Revenue

Wall Street analysts see Illumina reporting earnings of $1.11 per share on revenue of $786.37 million.

In the same quarter last year, Illumina reported EPS of 82 cents on revenue of $662 million. If the company were to match the consensus estimate when it reports Monday, EPS would be up 35.37 percent. Sales would be up 18.79 percent from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:

 

Quarter Q1 2018 Q4 2017 Q3 2017 Q2 2017
EPS Estimate 1.01 1.18 0.99 0.69
EPS Actual 1.45 1.44 1.11 0.82

Stock Performance

Over the last 52-week period, shares are up 70.82 percent. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The most common rating by analysts on Illumina stock is a Neutral. The strength of this rating has maintained conviction over the past three months.

Posted-In: Earnings News

 

Related Articles (ILMN)

View Comments and Join the Discussion!

Insider Buys Of The Week: AT&T, GE, Salesforce

A Peek Into The Markets: US Stock Futures Flat Ahead Of Pending Home Sales Index